Skip to main content
SpringerPlus

Table 4 Medicare Part D plan characteristics over time

From: Patient costs of breast cancer endocrine therapy agents under Medicare Part D vs with generic formulations

 

2007

2010

2011 a

% Change in median, 2007 to 2011

Number of Plans in Each State (Median; Range)

51 (43–64)

41 (34–49)

33 (28–38)

−35.3

Mean Monthly Drug Premium in Each State (Median $, Range)

36.09 (31.72-40.69)

46.72 (35.12-53.01)

57.08 (44.93-62.97)

+58.2

  1. aFirst full year when generic alternatives to brand name aromatase inhibitors were made available to Medicare Part D beneficiaries.
Back to article page